Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells

Cancer Gene Therapy volume 18, pages 467–477 (2011)Cite this article

Subjects

Abstract

Soluble TRAIL and adenovirus (ad)-TRAIL exhibit a strong antitumor effect by inducing apoptosis. Vorinostat is the histone deacetylase (HDAC) inhibitor that induces cell death in cancer cell lines and regulates the expression of epigenetically silenced genes, such as Coxackie adenoviral receptor (CAR), the receptor for adenoviral entry. We propose a new strategy in which vorinostat will induce high expression of ad-TRAIL and a strong antitumor response, and investigated the mechanism involved. The effect of vorinostat on transcription and expression of TRAIL from ad-TRAIL-transduced lung cancer cells were confirmed by reverse transciption-PCR (RT-PCR), quantitative real time-PCR and western blot assay. Anti-tumor effects were measured after cotreatment of vorinostat and ad-TRAIL, and the drug interactions were analyzed. After combined treatment of vorinostat and ad-TRAIL, apoptosis and western blot assays for Akt, Bcl-2 and caspase were performed. Vorinostat increased the expression of CAR in lung cancer cell lines and increased the expression of luciferase (luc) from ad-luc-transduced cells and TRAIL from ad-TRAIL-transduced cells. RT-PCR and quantitative real time-PCR, after sequential vorinostat treatment, revealed that vorinostat may enhance TRAIL expression from ad-TRAIL by increasing transduction through enhanced CAR expression and increasing adenoviral transgene transcription. Combined vorinostat and ad-TRAIL treatment showed the synergistic anti-tumor effect in lung cancer cell lines. Combined vorinostat and ad-TRAIL induced stronger apoptosis induction, suppression of NF-κB activation and breakdown of the anti-apoptotic molecule Bcl-2. In conclusion, the vorinostat synergistically enhanced the anti-tumor effect of ad-TRAIL by (1) increasing adenoviral transduction through the increased expression of CAR and (2) increasing adenoviral transgene (TRAIL) transcription in lung cancer cell lines.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Hemminki A, Alvarez RD . Adenoviruses in oncology: a viable option? BioDrugs 2002; 16: 77–87.

    Article  Google Scholar 

  2. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320–1323.

    Article  CAS  Google Scholar 

  3. Jee YS, Lee SG, Lee JC, Kim MJ, Lee JJ, Kim DY et al. Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients. Anticancer Res 2002; 22: 2629–2634.

    CAS  Google Scholar 

  4. Wang Y, Wang S, Bao Y, Ni C, Guan N, Zhao J et al. Coxsackievirus and adenovirus receptor expression in non-malignant lung tissues and clinical lung cancers. J Mol Histol 2006; 37: 153–160.

    Article  CAS  Google Scholar 

  5. Gray SG, Ekstrom TJ . The human histone deacetylase family. Exp Cell Res 2001; 262: 75–83.

    Article  CAS  Google Scholar 

  6. Lee CT, Seol JY, Park KH, Yoo CG, Kim YW, Ahn C et al. Differential effects of adenovirus-p16 on bladder cancer cell lines can be overcome by the addition of butyrate. Clin Cancer Res 2001; 7: 210–214.

    CAS  Google Scholar 

  7. Dion LD, Goldsmith KT, Tang DC, Engler JA, Yoshida M, Garver Jr RI . Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. Virology 1997; 231: 201–209.

    Article  CAS  Google Scholar 

  8. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R . FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247–1252.

    Article  CAS  Google Scholar 

  9. VanOosten RL, Earel Jr JK, Griffith TS . Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis 2007; 12: 561–571.

    Article  CAS  Google Scholar 

  10. Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O . Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med 2007; 9: 440–451.

    Article  CAS  Google Scholar 

  11. Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai le M et al. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2 L/TRAIL. Int J Cancer 2006; 119: 944–954.

    Article  CAS  Google Scholar 

  12. Carlisi D, Lauricella M, D’Anneo A, Emanuele S, Angileri L, Di Fazio P et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer 2009; 45: 2425–2438.

    Article  CAS  Google Scholar 

  13. Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK . Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther 2009; 8: 1596–1605.

    Article  CAS  Google Scholar 

  14. Seol JY, Park KH, Hwang CI, Park WY, Yoo CG, Kim YW et al. Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther 2003; 10: 540–548.

    Article  CAS  Google Scholar 

  15. Lee CT, Lee YJ, Kwon SY, Lee J, Kim KI, Park KH et al. In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27. Cancer Res 2006; 66: 372–377.

    Article  CAS  Google Scholar 

  16. Bauerschmitz GJ, Barker SD, Hemminki A . Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). Int J Oncol 2002; 21: 1161–1174.

    CAS  Google Scholar 

  17. Fan S, Maguire CA, Ramirez SH, Bradel-Tretheway B, Sapinoro R, Sui Z et al. Valproic acid enhances gene expression from viral gene transfer vectors. J Virol Methods 2005; 125: 23–33.

    Article  CAS  PubMed  Google Scholar 

  18. Goldsmith ME, Kitazono M, Fok P, Aikou T, Bates S, Fojo T . The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. Clin Cancer Res 2003; 9: 5394–5401.

    CAS  PubMed  Google Scholar 

  19. Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP et al. Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 2003; 63: 847–853.

    CAS  PubMed  Google Scholar 

  20. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673–682.

    Article  CAS  Google Scholar 

  21. Griffith TS, Lynch DH . TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10: 559–563.

    Article  CAS  Google Scholar 

  22. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL . Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165: 2886–2894.

    Article  CAS  PubMed  Google Scholar 

  23. Griffith TS, Stokes B, Kucaba TA, Earel Jr JK, VanOosten RL, Brincks EL et al. TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 2009; 9: 9–19.

    Article  CAS  PubMed  Google Scholar 

  24. Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF et al. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 2005; 280: 10025–10033.

    Article  CAS  Google Scholar 

  25. Bremer E, van Dam GM, de Bruyn M, van Riezen M, Dijkstra M, Kamps G et al. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Mol Ther 2008; 16: 1919–1926.

    Article  CAS  Google Scholar 

  26. Imre G, Gekeler V, Leja A, Beckers T, Boehm M . Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 2006; 66: 5409–5418.

    Article  CAS  Google Scholar 

  27. Reed JC . Bcl-2 family proteins. Oncogene 1998; 17: 3225–3236.

    Article  Google Scholar 

  28. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O’Reilly LA et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63: 4460–4471.

    CAS  Google Scholar 

Download references

Acknowledgements

This study is supported by grants from the Korea Science and Engineering Foundation (2008-00728) to C-T Lee.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

    D R Kim, M-Y Park, H-I Yoon, J H Lee & C-T Lee

  2. Division of Pulmonology and Critical Care Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea

    D R Kim, M-Y Park, H-I Yoon, J H Lee & C-T Lee

  3. Department of Biology, University of Virginia, Charlottesville, VA, USA

    C-S Lee

  4. Department of Molecular Tumor Biology and Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Korea

    S-H Shim & M-W Sung

  5. Department of Smart Foods and Drugs and Indang Institute of Molecular Biology, Inje University, Seoul, Korea

    Y-S Kim

Authors
  1. D R Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M-Y Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C-S Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S-H Shim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H-I Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J H Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M-W Sung
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y-S Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C-T Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C-T Lee.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, D., Park, MY., Lee, CS. et al. Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells. Cancer Gene Ther 18, 467–477 (2011). https://doi.org/10.1038/cgt.2011.11

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2011.11

Keywords

This article is cited by

Search

Advanced search

Quick links